All immunotherapy articles
-
NewsBoosted BCG vaccine strategy significantly reduces tuberculosis relapse
A new study reveals that combining an immunotherapy with the traditional Bacille Calmette-Guérin (BCG) vaccine drastically lowers the risk of TB relapse in preclinical models.
-
NewsGut, airway and tumor microbes emerge as promising predictors of immunotherapy response in lung cancer
A comprehensive review systematically evaluates the microbiome’s role in lung cancer immunotherapy. Authors synthesized evidence covering microbial communities in the oral cavity, airways, lung tumors and gut, and their connections to treatment efficacy and immune‑related adverse events.
-
NewsBacteria found in lung tumors may boost immune response to cancer
New preclinical study shows bacteria in lung tumors may boost the activation of innate immune cells in the presence of a common vitamin metabolite.
-
NewsGut-pancreas immune crosstalk may offer new therapeutic strategies for pancreatic cancer
A new study reports that immune responses produced in lymph nodes shared by the liver, pancreas and intestine shape T-cell tolerance. This cross-organ immune rewiring increases T-cell infiltration into pancreatic tumors, pointing to potential new approaches for hard-to-treat pancreatic cancers.
-
NewsAlbumin is prevented from crossing the placenta – opening opportunities for design of long-acting biologic medicines
Researchers have uncovered that the placenta distinguishes between antibodies and albumin, a finding that may reshape the future design of biologic medicines with reduced fetal exposure.
-
NewsStable RNA elements open new possibilities for mRNA therapeutics
New research has discovered compact viral RNA elements that can make mRNA more stable, and could provide a simple way to develop longer-lasting and more efficient mRNA technologies for vaccines and other RNA-based therapeutics.
-
NewsWorld’s first oral microbiome-based nanomedicine to supercharge anti-cancer immunity
Researchers have successfully developed the world’s first oral, microbiome-based nanomedicine which enhances the ability of immune cells to attack cancer cells.
-
NewsGut microbiome: The hidden architect of liver cancer immunotherapy response
A comprehensive review synthesizes current advances linking gut bacteria to immunotherapy outcomes in hepatocellular carcinoma (HCC), the most common type of primary liver cancer.
-
NewsMicrobes rewrite the rules of cancer immunotherapy by triggering immunogenic cell death
A new study reveals that microbiota and their metabolites can effectively reprogram immunogenic cell death (ICD), a unique form of cell death that activates the body‘s immune system against tumors, transforming immunologically “cold” therapy-resistant tumors into “hot” responsive ones.
-
NewsTrial tests virus-immunotherapy combination for neuroendocrine tumors
A phase I clinical trial is testing whether a tumor-targeting virus can help immunotherapy work more effectively against aggressive neuroendocrine tumors that often resist treatment. The ongoing study has completed its first three dose levels with no severe treatment-related side effects reported to date.
-
NewsMicrobiome insights may help predict immunotherapy benefit in kidney cancer
City of Hope researchers report that gut microbiome composition may influence how patients respond to immunotherapy combinations in metastatic renal cell carcinoma, pointing to a potential biomarker that could help guide treatment selection in the future. The microbiome is a rising focus at City of Hope, highlighted ...
-
NewsLargest-ever Canadian clinical trial tests ‘poop pills’ to improve immunotherapy for lung cancer
For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. A clinical trial will pair immunotherapy with fecal microbiota transplantation (FMT) with the goal of safely increasing treatment effectiveness. If successful, it could provide new treatment options for people with lung cancer.
-
NewsFecal microbiota transplantation improves response to immunotherapy in advanced kidney cancer
A new study provides compelling evidence that fecal microbiota transplantation (FMT) can enhance the effectiveness of immunotherapy in patients with advanced metastatic renal cell carcinoma (mRCC).
-
NewsGut bacteria molecule boosts lung cancer treatment response
Researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to lung cancer immunotherapy treatment in mice and can now be made into a drug for testing in humans.
-
NewsVictoria’s Secret grant backs cutting-edge ovarian cancer research
Promising ovarian cancer research by Melanie Rutkowski, PhD, at the University of Virginia Comprehensive Cancer Center has won $700,000 in support from the Victoria’s Secret Global Fund for Women’s Cancers in partnership with Pelotonia and AACR, the American Association for Cancer Research.
-
NewsGut bacterium impairs liver cancer treatment, inducing immunotherapy resistance
Researchers discovered that transplanting the gut bacterium Phocaeicola vulgatus into mouse models of liver cancer induced immunotherapy resistance. The finding is consistent with clinical observations in patients, showing that patients with low levels of P. vulgatus responded better to treatment.
-
NewsMERIT grant awarded to study cure for HIV
A scientific team has received an NIH MERIT Award to provide long-term grant support to study a handful of people who have managed to clear HIV after a stem cell transplant and those who did not.
-
NewsWhy killer cells can lapse into ‘exhausted’ CD8+ T cells that no longer can stem disease
In a detailed study of exhausted T cell subsets researchers show that a transcriptional repressor called Gfi1 is a key regulator of the subset formation of exhausted CD8+ T cells and may offer a key to reducing exhaustion.
-
NewsGut microbes key to understanding how exercise boosts cancer immunity
A new study shows how exercise improves cancer outcomes and enhances response to immunotherapy in mice by reshaping the gut microbiome. These benefits are driven by a specific compound called formate, which is produced by gut bacteria in exercised mice.
-
NewsCentauri Therapeutics selects first clinical candidate for immunotherapeutic treatment of Gram-negative bacterial infections
Centauri Therapeutics Limited has announced the selection of its first clinical candidate in the ABX-01 programme. The compound is designed to target serious Gram-negative bacterial infections in the lung.